Yongsheng Chen1, Yimin Shen2, Daniel Moiseev1, Zafar Wazir1, Bo Hu1, and Jun Li1
1Neurology, Wayne State University School of Medicine, Detroit, MI, United States, 2Radiology, Wayne State University School of Medicine, Detroit, MI, United States
Synopsis
Quantitative MRI (qMRI) methods were developed to measure T1, T2, proton
density, and MTR of mouse sciatic nerve in-vivo. Pmp22+/- mouse, an animal
model of hereditary neuropathy with liability to pressure palsies (HNPP), was
imaged at 3- and 6-month of age. The imaging demonstrated an increase of MTR, and
a decrease of proton density and T1 in the Pmp22+/-
nerves, compared with those in wild-type nerves. These qMRI changes correlate
with the growth of HNPP pathology – tomacula formed by excessive myelin folding
over time. Ongoing experiment is to determine the pathological and
molecular substrates responsible for the qMRI findings.
Introduction
Hereditary
neuropathy with liability to pressure palsies (HNPP) is an autosomal-dominantly
inherited peripheral nerve disease caused by a heterozygous deletion of the human
PMP22 gene.1 HNPP is characterized by focal myelin
thickenings known as ‘tomacula’ in peripheral nerves (Figure 1).2, 3 Our studies revealed that
haploinsufficiency of PMP22 results
in disruption of myelin junctions leading to excessive myelin permeability in
HNPP nerves4, 5 and severe fatigue in patients with
HNPP6. These discoveries also result in a
potential therapy to treat HNPP.7 Hence, there is a pressing need to
develop monitoring biomarkers in patients with HNPP. Our quantitative MRI (qMRI)
study has shown a high nerve proton density (PD) strongly correlated with
fatigue severity in persons with HNPP.6 To determine molecular substrates
responsible for these HNPP qMRI changes, we have studied a HNPP mouse model (Pmp22+/-)2, 3 that well recapitulates nerve pathology in HNPP patients. This
study measured mouse sciatic nerve T1, T2, PD, and magnetization transfer ratio
(MTR) in vivo on a 7T preclinical
scanner (Bruker AV4 Neo BioSpec, ParaVison 360 software) which will be
correlated with histological and molecular changes in the same nerves. Methods
Isoflurane
anesthetized (3-5% isoflurane in medical air for induction, 1.3-1.5% for
maintenance), spontaneously breathing Pmp22+/-
(n = 4, 75% male) and Pmp22+/+ (n = 4,
75% male) mice were placed into the 7T scanner at the prone position and scanned using
a volumetric Tx/Rx coil (35 mm in diameter) to acquire bilateral sciatic nerve
image in the axial plane. Each animal was imaged twice at 3- and 6-month old then
repeated 5 days after the 6-month scan for the test-retest reliability purpose.
The imaging protocol includes: i) a 2D T2 weighted RARE (rapid acquisition with
relaxation enhancement) sequence for anatomical images. ii) a 2D multi-slice
multi-echo sequence for simultaneously T2 and PD mapping using 16 echoes from
11 ms to 176 ms and a three-parameter mono-exponential fitting. A TR = 8s (≥ 5
times T1) was used to minimize the T1 effect and to get a relatively pure PD value. iii)
a 3D FLASH (fast low angle shot) sequence with and without an MT pulse for
quantifying MTR. The MT pulse was a single-lobe sinc pulse with Gaussian apodization, 15 ms duration, and 1.5k Hz
off-resonance. iv) a single slice variable TR RARE sequence for T1 mapping which
had 8 TRs from 350 ms to 7750 ms. The imaging resolution was 0.12 x 0.12 x 0.8 mm3.
All sequences had 20 slices except for the single slice T1 mapping. A hermite
pulse of 5.2 ms/1039 Hz duration/bandwidth followed by a 2-ms-long gradient
spoiler was used to suppress fat for all sequences.8
Two
independent raters manually measured regions of interest (ROIs) for bilateral sciatic
nerves (Figure 2). One of the raters measured all data again 7 days later. The
mean value of pixels within the ROI was calculated for T1, T2, PD, and MTR. Wilcoxon
rank-sum test was used for the comparison between groups. Paired t-test was
used to compare longitudinal changes for each group. The ±95% confidence
interval of Bland-Altman analysis and intraclass correlation coefficient (ICC)
were used to evaluate the method's test-retest, inter-rater, and intra-rater
reliability.Results
Compared with wild-type (Pmp22+/+)
mice, HNPP (Pmp22+/-) mice had a decreased
PD, T1, T2; and a high MTR at 6 months of age, but these differences were not
seen at 3 months of age (Figures 3A to 3D). While there was a longitudinal
increase of MTR, decrease of PD and T1 for Pmp22+/-
mice over the 3-month interval, the T2 value was unchanged (Figures 3E to 3H). The
test-retest analyses demonstrated a moderate (ICC = 0.5~0.75) agreement for MTR,
PD, and T1 assays, and a good (ICC = 0.75~0.9) agreement for T2 (Figure 4).
Inter-rater analysis showed good reliability for T1 and T2 measures, and excellent (ICC > 0.9) reliability for PD and MTR measures (Figures 5A to 5D). All
parameters had good to excellent intra-rater reliability (Figures 5E to 5H).Discussion and Conclusions
Pmp22+/- mouse is a well-established model for HNPP.2-5 Tomacula formed by excessive myelin folding increases the
myelin content per unit of nerve volume. Tomacula gradually increases from
3-month to 6-month of age in both prevalence and their sizes. This pathological
change appears to correlate with the qMRI findings indicating an increase of
myelin contents and a decrease of water content. However, at the late stage of
the disease (>10 months of age), segmental demyelination takes place while
tomacula degenerate. We would expect to see an increase in PD and T1 due to a demyelination-induced increase in water content, and a decrease in MTR due to
degeneration of tomacula, leading to a decrease of myelin content in the aged
animals.
In
conclusion, this pilot study demonstrated the reliability and feasibility of
the quantitative MRI methods to monitor the progression of peripheral nerve pathologies
in the HNPP mouse model. The ongoing investigation will determine the molecular
substrates responsible for the MRI findings.Acknowledgements
Funding
sources: NIH/NINDS R01NS115748 and NIH/NCATS R21TR003312.References
1. Li J, Parker B, Martyn C, Natarajan C,
Guo J. The PMP22 gene and its related diseases. Molecular neurobiology
2013;47:673-698.
2. Adlkofer K, Frei R, Neuberg DH-H,
Zielasek J, Toyka KV, Suter U. Heterozygous peripheral myelin protein
22-deficient mice are affected by a progressive demyelinating tomaculous
neuropathy. Journal of Neuroscience 1997;17:4662-4671.
3. Adlkofer K, Martini R, Aguzzi A,
Zielasek J, Toyka KV, Suter U. Hypermyelination and demyelinating peripheral
neuropathy in Pmp22-deficient mice. Nature genetics 1995;11:274-280.
4. Guo J, Wang L, Zhang Y, et al. Abnormal
junctions and permeability of myelin in PMP22‐deficient nerves. Annals of neurology
2014;75:255-265.
5. Hu B, Arpag S, Zhang X, et al. Tuning
PAK activity to rescue abnormal myelin permeability in HNPP. PLoS genetics
2016;12:e1006290.
6. Fritz NE, Chen Y, Waters L, et al.
Fatigue in patients with hereditary neuropathy with liability to pressure
palsies. Annals of Clinical and Translational Neurology 2020;7:1400-1409.
7. Li J, Hu B. Treatment for hereditary
neuropathy with liability to pressure palsies (HNPP). US Patent 10507211, 2019.
8. Giorgetti E, Obrecht M, Ronco M, et al.
Magnetic Resonance imaging as a Biomarker in Rodent peripheral nerve injury
Models Reveals an Age-Related impairment of nerve Regeneration. Scientific
reports 2019;9:1-18.